⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156910 | 1.00 | — | — | |
| SCHEMBL943559 | 1.00 | — | — | |
| SCHEMBL20399494 | 0.97 | — | — | |
| SCHEMBL28221014 | 0.97 | CYP2D6 (0.37) | — | |
| SCHEMBL7013790 | 0.97 | CYP2D6 (0.37) | — | |
| SCHEMBL446417 | 0.97 | — | — | |
| SCHEMBL446149 | 0.97 | — | — | |
| SCHEMBL1676000 | 0.90 | — | — | |
| SCHEMBL1892822 | 0.90 | — | — | |
| SCHEMBL30821 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| CN-110248949-A | Immunoproteasome inhibitor | 普林斯匹亚生物制药公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-108368090-A | Compounds as Immunomodulators | 百时美施贵宝公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-2018136401-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| CN-104302290-B | Hepatitis c virus inhibitors | 百时美施贵宝公司 | 2017-10-24 | — | — | CN | disclosed |
| CN-104321326-B | The Imidazopyridazine of amino substitution | 拜耳医药股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-104981470-B | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | 拜耳制药股份公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106188027-A | Heteroaromatic analog derivative and the application in medicine thereof | 广东东阳光药业有限公司 | 2016-12-07 | — | — | CN | disclosed |
| EP-1858885-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| CN-101003515-A | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2007-07-25 | — | — | CN | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| CN-1882572-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006092574-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006092573-A1 | INDAZOLYLAMINO QIONAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| CN-1656081-A | 4-Anilinoquinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-08-17 | — | — | CN | disclosed |
| EP-1487806-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astrazeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082831-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |